Status:
COMPLETED
Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade
Lead Sponsor:
Sarah Blair, M.D.
Collaborating Sponsors:
Medtronic Surgical Technologies
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
The purpose of this research study is to find out more about distinguishing between cancerous and non-cancerous breast cancer cells at the edges of tumors. Using an FDA approved device to remove tumor...
Detailed Description
Breast conservation therapy (BCT) is the standard surgical treatment for breast cancer. The goal of BCT is total excision of the malignant lesion while simultaneously preserving the cosmetic appearanc...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Women or men with an established diagnosis of an invasive ductal carcinoma
- Women or men with tumors \> 1cm
- Women undergoing Breast Conservation Operations
- Women or men may have had prior chemotherapy as long as their treatment was completed \>2 weeks prior to enrollment with recovery from any toxicities
- Exclusion Criteria
- No established diagnosis of breast cancer
- Women or men with tumors \<1 cm
- Women or men undergoing total mastectomy
- Women or men who have had prior radiation
Exclusion
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00972010
Start Date
July 1 2009
End Date
November 1 2010
Last Update
July 12 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Thornton Hospital
La Jolla, California, United States, 92037
2
Rebecca and John Moores Cancer Center
La Jolla, California, United States, 92093
3
UCSD Medical Center
San Diego, California, United States, 92103